Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Helen Ross, MD
Rush University
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California San Diego Moores Cancer Center
La Jolla, California, United States
- Kaiser Permanente Oakland Medical Center
Oakland, California, United States
- Kaiser Permanente Roseville Medical Center
Roseville, California, United States
- Kaiser Permanente San Francisco Medical Center
San Francisco, California, United States
- Kaiser Permanente Santa Clara Medical Center
Santa Clara, California, United States
- Kaiser Permanente Vallejo Medical Center
Vallejo, California, United States
- Rush University Medical Center
Chicago, Illinois, United States
- Missouri Baptist Medical Center
St Louis, Missouri, United States
- Washington University Siteman Cancer Center
St Louis, Missouri, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- New Hampshire Oncology - Hematology, Pa
Manchester, New Hampshire, United States
- Hematology Oncology Associates of Central New York, P.C.
East Syracuse, New York, United States
- Suny Upstate Medical University
Syracuse, New York, United States
- Ohio State University
Columbus, Ohio, United States
- University of Wisconsin
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Dec 2023
- Primary completion
- 30 Nov 2026
- Completion
- 30 Nov 2026
- Last update posted
- 9 Jun 2026
- Registered enrollment
- 178
- Registry id
- NCT05798663
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.